NeuroScientific Biopharmaceuticals Limited (ASX: NSB)
Health Care · Biotechnology · AU
AU$0.07
+12.07% today · -64.9% 1Y
NeuroScientific Biopharmaceuticals Limited (ASX: NSB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $18.16M and employs 9 people.
Over the last twelve months the share price has lost 64.9%, trading between 0.06 and 0.19.
Tweenvest scores NeuroScientific Biopharmaceuticals Limited across four factors: quality 45/100, value 60/100. Its strongest factor is value.
NSB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $18.16M
- Revenue (TTM)
- $212.05K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- AU$0.19
- 52-week low
- AU$0.06
- Avg volume (3M)
- —
- Shares outstanding
- 389.72M
- Employees
- 9
- Next earnings
- —
About NeuroScientific Biopharmaceuticals Limited
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
- ISIN
- AU0000012973
- Founded
- 2002
- Listed since
- Jul 27, 2018
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.